EVOK On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt

evoke pharma inc (EVOK) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EVOKE PHARMA INC (EVOK)
\

Related News

No related news articles were found.

evoke pharma inc (EVOK) Related Businessweek News

No Related Businessweek News Found

evoke pharma inc (EVOK) Details

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. The company was founded in 2007 and is headquartered in Solana Beach, California.

6 Employees
Last Reported Date: 03/6/19
Founded in 2007

evoke pharma inc (EVOK) Top Compensated Officers

Co-Founder, CEO, President & Director
Total Annual Compensation: $733.1K
Co-Founder, Chief Business Officer, Executive...
Total Annual Compensation: $557.2K
Chairman of the Board
Total Annual Compensation: $47.5K
Chief Medical Officer
Total Annual Compensation: $501.4K
Compensation as of Fiscal Year 2018.
evoke pharma inc
Evoke Pharma, Inc. Receives Notice Of Non-Compliance From Nasdaq

On May 15, 2019, Evoke Pharma, Inc. received a letter from the Nasdaq staff indicating that, for the last thirty consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until November 11, 2019, to regain compliance. The letter states that the Nasdaq staff will provide written notification that the Company has achieved compliance with Rule 5550(a)(2) if at any time before November 11, 2019, the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of ten consecutive business days. The Nasdaq letter has no immediate effect on the listing or trading of the Company’s common stock and the common stock will continue to trade on The Nasdaq Capital Market under the symbol “EVOK.” The Company intends to monitor the bid price of its common stock and consider available options if its common stock does not trade at a level likely to result in the Company regaining compliance with Nasdaq’s minimum bid price rule by November 11, 2019. If the Company does not regain compliance with Rule 5550(a)(2) by November 11, 2019, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it appears to the Nasdaq staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, the Nasdaq staff would notify the Company that its securities would be subject to delisting. In the event of such a notification, the Company may appeal the Nasdaq staff’s determination to delist its securities, but there can be no assurance the Nasdaq staff would grant the Company’s request for continued listing.

Evoke Pharma, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2019

Evoke Pharma, Inc. reported unaudited earnings results for the first quarter ended March 31, 2019. For the quarter, the company reported loss from operations of $1,969,895 against $2,417,611 a year ago. Net loss was $1,965,266 against $1,982,786 a year ago. Net loss per share of common stock, basic and diluted was $0.11 against $0.13 a year ago.

Evoke Pharma, Inc. Announces Board Changes

On May 2, 2019, Scott L. Glenn resigned from the Board of Directors of Evoke Pharma, Inc. In addition, the Board has determined to reassign Todd Brady, M.D., Ph.D. from Class I of the Board to Class II of the Board and, accordingly, Dr. Brady will stand for re-election at the 2021 Annual Meeting of Stockholders. Further, the Board appointed Dr. Brady as a member of the Audit Committee to replace Mr. Glenn as an Audit Committee member.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

EVOK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EVOK.
View Industry Companies
 

Industry Analysis

EVOK

Industry Average

Valuation EVOK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact EVOKE PHARMA INC, please visit www.evokepharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.